ArticleFrontiers in oncology2021
Acetate Promotes a Differential Energy Metabolic Response in Human HCT 116 and COLO 205 Colon Cancer Cells Impacting Cancer Cell Growth and Invasiveness.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.Gut microbes · 2026Review
- Article
- Gut microbiota-metabolism axis in digestive tumors: Emerging targets for novel therapies (Review).Experimental and therapeutic medicine · 2026Review
- Gut microbiota metabolites positively impacts chemotherapy effects in colorectal cancer.Cell biology and toxicology · 2026Article
- Lactiplantibacillus plantarum MTCC 25433 and Quercetin Blend Ameliorate Benzo[a]pyrene-Induced Gut Dysregulation in a Murine Model.Current microbiology · 2025Article
- Energy Metabolism Profiling of Human Colorectal Tumours.Journal of cellular and molecular medicine · 2025Article
- Polyp and tumor microenvironment reprogramming in colorectal cancer: insights from mucosal bacteriome and metabolite crosstalk.Annals of clinical microbiology and antimicrobials · 2025Article
- Energy Metabolism Behavior and Response to Microenvironmental Factors of the Experimental Cancer Cell Models Differ from that of Actual Human Tumors.Mini reviews in medicinal chemistry · 2025Review
- Short-chain fatty acids play a positive role in colorectal cancer.Discover oncology · 2024Review
- Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study.Frontiers in pharmacology · 2024Article
- A novel "microbiota-host interaction model" to study the real-time effects of fermentation of non-digestible carbohydrate (NDCs) on gut barrier function.Current research in food science · 2024Article
- Mitochondrial Proteins as Metabolic Biomarkers and Sites for Therapeutic Intervention in Primary and Metastatic Cancers.Mini reviews in medicinal chemistry · 2024Review
- Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms.PloS one · 2024Article
- Metabolic signatures and potential biomarkers for the diagnosis and treatment of colon cancer cachexia.Acta biochimica et biophysica Sinica · 2023Article
- Inhibition of TRAP1 Accelerates the DNA Damage Response, Activation of the Heat Shock Response and Metabolic Reprogramming in Colon Cancer Cells.Frontiers in bioscience (Landmark edition) · 2023Article
- Role of microencapsulatedFrontiers in microbiology · 2023Article
- Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy?Frontiers in immunology · 2023Review
- Cultivation of gastrointestinal microbiota in a new growth system revealed dysbiosis and metabolic disruptions in carcinoma-bearing rats.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under dysbiosis, a gut metabolic disorder, short-chain carboxylic acids (SCCAs) are secreted to the lumen, affecting colorectal cancer (CRC) development. Butyrate and propionate act as CRC growth inhibitors, but they might also serve as carbon source. In turn, the roles of acetate as metabolic fuel and protein acetylation promoter have not been clearly elucidated. To assess whether acetate favors CRC growth through active mitochondrial catabolism, a systematic study evaluating acetate thiokinase (AcK), energy metabolism, cell proliferation, and invasiveness was performed in two CRC cell lines incubated with physiological SCCAs concentrations. In COLO 205, acetate (+glucose) increased the cell density (50%), mitochondrial protein content (3-10 times), 2-OGDH acetylation, and oxidative phosphorylation (OxPhos) flux (36%), whereas glycolysis remained unchanged
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.